Adams Business Associates, (ABA) provides practical business support for High Technology Businesses.
Our specialised focus is on Life Sciences, Bio-Research, Diagnostics, Healthcare and Biotechnology. ABA provides business development, stategic marketing, B2B services and reports based on sound management and technical experience.
Together we identify effective marketing decisions directed to improving profitability and the long term success of your business with Independent assessments and strategies controlled by Financial Analysis and Health Technology Assessment.
We use our detailed experience for each stage of your business or product development from: Design through to Development and to Launch.
Latest Items
Life Science Research Global Library: EMEA Coverage & Global Status at May 2018.
All eight (8) regional ABA Global Library reports were made available during 2017 with 2016 as the market base line with business and commercial developments during the year covered by Appendices. During 2017 major full new analyses were prepared that detailed the actual outcomes for 2016, plus Individual country budgets for 2017 and those proposed for 2018. For all these reports new further sections have been added that detail the events and market quantification for 2017 with projections to 2022.
These reports are for:
- ABA 348.3A - Middle East, Arabia & North Africa.
- ABA 350.3A Vol. 1 Eastern Majors of China, India & Japan with Pakistan, Hong Kong, Bangladesh & Sri Lanka.
- ABA 355.3A Vol. 2. 11 Pacific region, including Australia & New Zealand.
- ABA 360.3A - Central & Eastern Europe.
- ABA 365.3A - Sub-Sahara & South Africa.
- ABA 370.3A - Latin & South America.
- ABA 374.3A - Western Europe.
- ABA 375.3 - North America: USA and Canada.
Full details of Contents Lists and Abstracts are available for each sector Link to Contents List & Abstract on Business Development page.
More information on the EMEA region reports can be found on the Articles Page.Diagnostics Report Series 2018 - Addition of Prion Analysis Report, ABA 315.
It has been a decade in the promise that the Prion Analysis report would be produced and now it has been achieved. A major hurdle for this sector has been that it was like searching in the haystack for something but not knowing what! The finding that this was due to a mis-folded protein at least indicated what was being sought. Advances have now been made not only in identifying features of this protein but also some of the genetic drivers. However, although analytical methods involving Imaging, in vivo and in vitro Diagnostics have been developed there is still much for the research fraternity to resolve. Not least of these is how a protein can cause infection with no RNA/DNA content, even if genetic drivers have been found.
The new report on Prion Analysis, ABA 315, adds to the other three fully updated reports with all activities and market dynamics to the end of 2017 and early 2018 throughout the Diagnostic series:
- Point-of-Care Tests - Personalised Medicine & POCT, ABA 310.
- Molecular Diagnostics - Technologies, Products &Services for MDx, ABA 298.
- Cell Based Assays - Technologies, Applications, Products & Services, ABA 413.
Full details of Contents Lists and Abstracts are available for each sector Link to Contents List & Abstract on Business Development page.